Alternatives to Iktos

Generative AI drug discovery suite spanning target ID, molecule design, biologics and clinical trial prediction.

Recursion OS pairs automated wet labs with AI models for AI drug discovery at up to 2 million weekly experiments.

Nimbus Therapeutics designs highly selective small-molecule drugs for oncology, immunology, and metabolic disease.

Recursion runs AI drug discovery as a lab-in-the-loop engine — automated cellular imaging at scale feeding generative chemistry and a clinical pipeline.

Owkin's K Pro is an autonomous AI scientist agent for biopharma R&D, turning multimodal patient data into drug discovery and clinical trial

Evotec is a life-science partner running AI-assisted drug discovery and Just–Evotec Biologics manufacturing.

Physics-based molecular simulation with AI for drug discovery and materials design.

Causal AI drug discovery pairing 20+ petabytes of cellular data with human genetics to find true disease targets

BenevolentAI applies a decade-built biomedical knowledge graph to drug target discovery and repurposing for biopharma R&D teams.

AI drug discovery engine pairing 2M weekly automated lab experiments with a 50+ PB proprietary dataset.

Open-source, self-hosted AI research assistant for drug discovery — molecular property prediction, virtual screening and PK/PD modeling on your own hardware.

Atomwise APEX Protocol screens 10 billion compounds in under 30 seconds for small-molecule drug discovery

Tempus pairs tumor DNA/RNA sequencing with AI precision oncology analytics to surface treatment and trial matches

SciSpace BioMed Agent runs multi-omics, variant prioritization, and drug repurposing analysis from plain-language biomedical prompts.

AI-CRISPR target discovery platform pairing AlgenCRISPR gene modulation with the AlgenBrain foundation model for causal immunology and

NExTNet pairs an evidence-backed life sciences Copilot with Explorer knowledge maps over a deterministic biomedical ontology.

AI-native pharma company using autonomous agents to find new uses for existing drugs and predict patient drug response

Isomorphic Labs uses AI drug discovery models to design novel molecules and predict how candidate drugs will perform.

Silico is Goodfire's interpretability agent for understanding and debugging the internals of your AI models.

Oncology real-world evidence platform combining high-fidelity patient data with AI-assisted cancer research insights.

All-in-human AI foundation models for precision neurology — vBx-1.0 predicts brain activity and therapy response from a blood draw.

Renamed: Deep 6 AI was acquired by Tempus AI in March 2025 and its trial matching folded into Tempus.

Benchling unifies ELN, LIMS, and AI agents for biotech R&D in one cloud platform.

FDA-cleared AI for cancer pathology: prostate, breast, GI and pan-cancer detection on H&E slides, plus Virchow foundation models for research.

Quibim turns MRI, CT and PET scans into regulatory-cleared quantitative imaging biomarkers for prostate, brain, liver, breast and lung.

Iambic Therapeutics pairs Enchant v3 and NeuralPLexer AI drug discovery with weekly wet lab readouts and a clinical-stage pipeline.

AI protein engineering that optimizes binding, stability, activity, and expression across wet-lab rounds.

Cellino's AI-guided optical bioprocessing automates personalized cell therapy manufacturing on the Nebula™ platform.

PathAI's AISight Dx brings FDA-cleared digital pathology and AI biomarker algorithms to labs and biopharma trials.

Dotmatics Luma Agent: agentic AI for regulated R&D that plans, executes, and documents scientific data analysis